Drug information provided by: Merative, Micromedex®
Ado-trastuzumab emtansine injection is used to treat HER2-positive metastatic breast cancer (cancer that has spread) in patients who have previously received other medicines (eg, trastuzumab, taxane medicine) that did not work well or whose cancer has returned during or within 6 months of completing treatment. It is also used as additional treatment in patients with HER2-positive early breast cancer who have cancer left after a taxane medicine and trastuzumab-based treatment.
HER2 protein is produced by some breast tumors. Ado-trastuzumab emtansine interferes with the growth of this protein which also prevents tumor growth. The tumor cells will then be destroyed by the body.
This medicine is to be given only by or under the immediate supervision of your doctor.
This product is available in the following dosage forms:
Portions of this document last updated: June 01, 2024
Copyright: © Merative US L.P. 1973, 2024. All rights reserved. Information is for End User's use only and may not be sold, redistributed or otherwise used for commercial purposes.
لا تُقدم Mayo Clinic الدعم للشركات أو المنتجات المُعلَّن عنها هنا. لكن تدعم العائدات الإعلانية رسالتنا غير الربحية.
تحقق من هذه الكتب الأكثر مبيعًا والعروض الخاصة على الكتب والنشرات الإخبارية من Mayo Clinic Press.
تساهم التبرّعات، وهي قابلة للخصم الضريبي، في دعم آخر التطورات في الأبحاث وطرق الرعاية لإحداث نقلة نوعية في الطب.